Standard IV antibiotic timing for cystic fibrosis lung flare-ups
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study standardizes how IV aminoglycoside antibiotics are given during a 14-day treatment for cystic fibrosis (CF) lung flare-ups. It may help make treatment more consistent and easier to manage for people who need IV antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (any gender) must be at least 6 years old at the first visit
- You must have a confirmed diagnosis of cystic fibrosis
- Your clinician plans to treat your current CF lung flare-up with a 14-day course of IV antibiotics
- You have had at least one positive Pseudomonas (Pa) culture within the past 2 years
- In the past 6 weeks, you should not have had ICU care, a collapsed lung (pneumothorax), or coughing blood (hemoptysis), and you should not have started IV antibiotics for this flare-up yet
- In the past 4 weeks, you should not have taken new CFTR-modulator meds, investigational treatments, or treatment for non-tuberculous mycobacteria
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a streamlined approach to managing sudden lung symptoms (pulmonary exacerbations) in children with cystic fibrosis. It aims to see if a simpler treatment plan works as well as standard care, which could mean less time in the hospital and fewer disruptions to daily life.
This study looks at how lung infections and inflammation affect people with cystic fibrosis during severe flare-ups. It aims to understand which antibiotics work best and why, so your care team can choose the right treatment for you.
This study aims to understand what causes and increases the risk of lung infections (exacerbations) in people with cystic fibrosis. It involves regular monitoring and sample collection at home and in the clinic to identify early warning signs.
This early-phase study tests how different doses of an inhaled medicine (amphotericin B) work and are tolerated. It includes healthy adults and people with cystic fibrosis (CF) to see if the dose schedule is safe and potentially beneficial.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.